These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650 [TBL] [Abstract][Full Text] [Related]
23. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E; AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675 [TBL] [Abstract][Full Text] [Related]
24. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. Zolopa AR; Berger DS; Lampiris H; Zhong L; Chuck SL; Enejosa JV; Kearney BP; Cheng AK J Infect Dis; 2010 Mar; 201(6):814-22. PubMed ID: 20146631 [TBL] [Abstract][Full Text] [Related]
25. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Luna B; Townsend MU Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Arastéh K; Yeni P; Pozniak A; Grinsztejn B; Jayaweera D; Roberts A; Hoy J; De Meyer S; Vangeneugden T; Tomaka F Antivir Ther; 2009; 14(6):859-64. PubMed ID: 19812449 [TBL] [Abstract][Full Text] [Related]
27. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. Hill A; Marcelin AG; Calvez V HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. Boffito M; Miralles D; Hill A HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907 [TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328 [TBL] [Abstract][Full Text] [Related]
31. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640 [TBL] [Abstract][Full Text] [Related]
32. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Arribas JR Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. Molina JM; Cohen C; Katlama C; Grinsztejn B; Timerman A; Pedro Rde J; Vangeneugden T; Miralles D; Meyer SD; Parys W; Lefebvre E; ; J Acquir Immune Defic Syndr; 2007 Sep; 46(1):24-31. PubMed ID: 17621237 [TBL] [Abstract][Full Text] [Related]
34. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. Brogan AJ; Mrus J; Hill A; Sawyer AW; Smets E HIV Clin Trials; 2010; 11(3):133-44. PubMed ID: 20736150 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S; Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272 [TBL] [Abstract][Full Text] [Related]
36. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain]. Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386 [TBL] [Abstract][Full Text] [Related]
37. Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients. Hill AM; Smith C HIV Clin Trials; 2007; 8(3):121-31. PubMed ID: 17621459 [TBL] [Abstract][Full Text] [Related]